The United Kingdom and the United States have established a important commercial pact that will guarantee no import taxes on UK drug shipments entering the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to raise funding on pharmaceuticals through the NHS. This pledge secures that tariffs on these key exports will remain at zero for a period of 36 months.
This deal is in response to previous warnings to significantly raise duties on patented drug imports, with potential rates floated as high as 100%.
"This deal with the United Kingdom bolsters the international landscape for innovative medicines and introduces long-overdue balance to transatlantic medicine commerce," a release noted.
Economic Importance
Pharmaceuticals constitute one of the Britain's biggest exports to the America, which is easily the largest buyer for leading companies like GSK and AstraZeneca.
Trade data show that in the year prior to last September, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This amount represented 17.4% of all goods exports in that span.
"This agreement protects jobs, stimulates funding and sets the stage for the UK to become a international leader for life sciences," a government official stated.
Specific British Pledges
The pact entails several notable pledges from the British government:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to double total health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The percentage drug companies must refund to the NHS to control costs will be restricted at fifteen percent. Previously, repayments topped twenty percent.
Recent Tensions
The pact follows a long-running row between the drug companies and the UK government over medicine costs and approval rates.
These tensions were exacerbated by assertions that US consumers were paying a premium for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been announced toward American operations.
The Science Minister acknowledged that the NHS had to spend more on medicines, noting that its spending on drugs had decreased as a share of its total funding over the past decade.
